| Bioactivity | Neptinib (NEP010) is an orally active derivative of Afatinib (HY-10261) that has stronger antitumor activity than Afatinib (HY-10261) by improving pharmacokinetics. Neptinib has a significant inhibitory effect on tumor growth in mouse non-small cell lung cancer models with different EGFR mutations. Neptinib has a certain inhibitory effect on the EGFR kinase family, with IC50 values ??of 0.24 nM, 7.25 nM, 0.46 nM and 1.79 nM for EGFRwt, EGFRL858R/T790M, EGFRL858R and EGFRT790M, respectively[1]. |
| CAS | 2085843-51-0 |
| Formula | C22H23ClFN5O2 |
| Molar Mass | 443.90 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yidong Feng, et al. "NEP010, a novel compound with minor structural modification from afatinib, exhibited significantly improved antitumor activity." European Journal of Pharmacology 946 (2023): 175620. |
Neptinib
CAS: 2085843-51-0 F: C22H23ClFN5O2 W: 443.90
Neptinib (NEP010) is an orally active derivative of Afatinib (HY-10261) that has stronger antitumor activity than Afatin
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.